Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671405 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
A Phase 1 study of Dyslipidaemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT06671405 is a Phase 1 study of Dyslipidaemia that has completed, run by AstraZeneca. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06671405, a Phase 1 study of Dyslipidaemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Itraconazole
- DRUG AZD0780
- DRUG Carbamazepine
- DRUG Ethinyl estradiol/levonorgestrel
Study Locations (1)
Maryland
- Research Site - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06671405
The ClinicalTrials.gov registry entry for NCT06671405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidaemia appearing as the primary indexed condition, and to 5 interventions - of which Midazolam is the first listed.
NCT06671405 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06671405 about?
NCT06671405 is a clinical study titled "An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions". An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered al...
What is the current status of trial NCT06671405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2024-09-25. Estimated completion is 2025-02-17.
What conditions does trial NCT06671405 study?
This clinical trial studies the following conditions: Dyslipidaemia.
What interventions are being tested in trial NCT06671405?
The interventions under investigation include: Midazolam (DRUG), Itraconazole (DRUG), AZD0780 (DRUG), Carbamazepine (DRUG), Ethinyl estradiol/levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT06671405?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671405 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.